Drug discovery companies will be able to utilize new multiple miRNA biomarkers to determine the efficacy of targeted drugs, in major therapeutic areas and when developing companion biomarker strategies for future clinical development.

 

MicroRNA profiling has rapidly become an indispensable technology with a whole catalogue of applications and new opportunities. Companion biomarkers are the most recent extension of the technology and are set to provide valuable clinical data to guide both pre-clinical and clinical studies. The system will use the robustness and specificity of miRNA to identify highly discriminatory biomarkers which, in turn, will guide patient prognosis, the selection of appropriate drug treatment, and monitoring of drug response. 

 

For further information on Sistemic’s new Companion Biomarker program, SistemRNA suite, and other Sistemic products and services please visit: www.sistemic.co.uk